A newly developed pill could offer a fresh approach to treating type 2 diabetes and obesity. Early research suggests it may help lower blood sugar and increase fat burning without reducing appetite or causing muscle loss, two common concerns associated with some current weight loss medications.
The findings, published in the journal Cell, come from researchers at Karolinska Institutet and Stockholm University.
A Different Approach From GLP-1 Drugs
Unlike popular GLP-1 medications such as Ozempic, which are delivered by injection and work by influencing appetite signals between the gut and brain, the new treatment takes a completely different path.
Instead of targeting hunger, the experimental drug activates metabolism inside skeletal muscle. Researchers say this approach improved blood sugar regulation and body composition in animal studies while avoiding several side effects often linked to GLP-1 therapies, including appetite suppression, muscle loss, and digestive issues.
